We assessed the association between 1,414 single nucleotide polymorphisms (SNPs) in genes involved in synthesis and metabolism of steroid hormones and insulin-like growth factor 1, and risk of breast cancer in situ (BCIS), with the aim of determining whether any of these were disease specific. This was carried out using 1,062 BCIS cases and 10,126 controls as well as 6,113 invasive breast cancer cases from the Breast and Prostate Cancer Cohort Consortium (BPC3). Three SNPs showed at least one nominally significant association in homozygous minor versus homozygous major models. ACVR2A-
) were associated with increased risk of BCIS; however, only the latter association was significant after correcting for multiple testing. Furthermore, INSR-rs10500204 was more strongly associated with the risk of BCIS than invasive disease in case-only analyses using the homozygous minor versus homozygous major model (OR hom 5 1.78, 95% CI 5 1.30-2.44, P hom 5 3.23 3 10 24 ). The SNP INSRrs10500204 is located in an intron of the INSR gene and is likely to affect binding of the promyelocytic leukemia (PML) protein. The PML gene is known as a tumor suppressor and growth regulator in cancer. However, it is not clear on what pathway the A-allele of rs10500204 could operate to influence the binding of the protein. Hence, functional studies are warranted to investigate this further.
Breast carcinoma in situ (BCIS) is a non-invasive breast cancer (BC) and a non-obligate precursor of invasive BC. Around 20% of all diagnosed breast tumors are non-invasive, and the most common in situ histological subtype, ductal carcinoma in situ (DCIS) corresponds to roughly 80% of BCIS diagnoses in the US.
1,2 While BCIS and invasive BC share epidemiological and, in part also genetic risk factors; it is important to identify any disease specific genetic risk factors, since only a fraction of existing BCIS tumors will progress to the invasive stage. 3, 4 Even though a growing number of common, low-penetrance susceptibility loci for invasive BC are being identified, [5] [6] [7] [8] [9] [10] [11] [12] comparatively few attempts to detect single nucleotide polymorphisms (SNPs) that are specific for breast carcinoma in situ (BCIS) have been made so far and of these several were underpowered. 4, [13] [14] [15] [16] A previous study conducted within the Million Women Study identified 2p-rs4666451 as being more strongly associated with BCIS risk than with invasive disease. 13 Additionally, a study within the Breast Cancer Association Consortium (BCAC) found that the SNP 5p12-rs10941679 was more strongly associated with DCIS and lower grade tumors. 15 We also reported the polymorphic variant CDKN2BAS-rs1011970 as a potential BCIS specific variant in a study conducted within the Breast and Prostate Cancer Cohort Consortium (BPC3). 4 More recently, the CCND1-rs75915166 and CCND1-rs554219 SNPs were found to be associated with low and intermediate grade DCIS risk within the BCAC study, 16 but these associations were also observed for invasive disease. 7, 9, 10 In a previous effort, we investigated 1,414 SNPs in 37 steroid hormone metabolism genes and 24 insulin-like growth factor 1 (IGF-I) pathway genes in relation to invasive BC susceptibility. 17 While only modest associations between the selected SNPs and BC were detected, there is convincing epidemiologic and molecular evidence that the concentrations of endogenous steroid hormones and IGF play a crucial role in modulating the risk of developing BC, [18] [19] [20] and it is possible that genetic variants in those pathways could influence early and non-invasive as well as more advanced stages of disease development. The purpose of our study was to evaluate these 1,414 SNPs in relation to BCIS risk, using up to 1,062 BCIS cases and up to 10,126 controls, as well as 6,113 invasive BC cases in a twophase association study within the BPC3.
Material and Methods

Study population
The BPC3 has been described extensively elsewhere. 21 Briefly, it consists of case-control studies nested within large, prospective cohorts in Europe, Australia and the US, which have both DNA samples and extensive questionnaire information collected at baseline. For our study, cases were women who had been diagnosed with BCIS after enrolment in one of the BPC3 cohorts. Controls were healthy women selected from each cohort. In addition, 6,113 incident, invasive BC cases from the BPC3 cohorts were also used to determine whether the variants were specific BCIS alleles (Table 1) . Relevant institutional review boards from each cohort approved the project and informed consent was obtained from all participants.
SNP selection and genotyping
In a first phase of the study, we analyzed 1,414 SNPs involved in steroid hormone and IGF-1 metabolism using 624 BCIS cases and 8,135 controls.
In the second phase of the study, we aimed to replicate the best associations (p < 0.001) using an additional set of 438 BCIS cases and 2,044 controls.
What's new?
While a growing number of common, low-penetrance susceptibility loci for invasive breast cancer are being identified, comparatively few attempts to detect single nucleotide polymorphisms (SNPs) specific for breast carcinoma in situ (BCIS) have been made. However, it is important to identify disease-specific genetic risk factors, since only a fraction of BCIS tumors will progress to the invasive stage. Our study indicates a possible association between the A-allele of INSR-rs10500204 and BCIS risk. INSR-rs10500204 is likely to affect binding of the promyelocytic leukemia protein, a tumor suppressor and growth regulator in cancer. Further epidemiological and functional studies are warranted to confirm the finding. The genotyping for the first phase was conducted using TaqMan assays (Applied Biosystems, Foster City, CA) and a custom Illumina Golden Gate array. More detailed information on genotyping and quality control is given elsewhere. 17 The genotyping of the second phase was performed using TaqMan as specified by the producer. Cases and controls were mixed in 384 well plates to genotype approximately the same number in each PCR run. Laboratory personnel were blinded to whether the samples were from cases or controls. To ensure the quality of the genotyping procedure, duplicate samples (8%) were also included. All SNPs were tested for HardyWeinberg equilibrium (HWE) using the control samples.
Statistical analyses
The association between SNPs and BCIS risk was investigated using an unconditional logistic regression and a co-dominant model of inheritance. To investigate the possible differential association of SNP alleles with invasive and non-invasive breast disease, we also carried out case-only analyses comparing BCIS cases with a reference group of invasive cases to assess whether the associations were specific for BCIS or shared with invasive BC. In addition, since DCIS is the most common form of BCIS, and information on histological subtype was available for 31% of the cases, we investigated associations between the SNP alleles and risk of DCIS. All analyses were adjusted for age at recruitment and cohort study. Since the SNPs for our study were selected on basis of an analysis comprising a total of 1,414 SNPs, we took all of these into account when adjusting the p value threshold of statistical significance for multiple testing. To account for residual linkage disequilibrium (LD) between the SNPs, we calculated the effective number of independent variants, M eff , using the SNP Spectral Decomposition approach (simpleM method). 13 All statistical tests were two sided and all statistical analyses were performed with SAS version 9.2.
In silico analyses
To assess any possible functional relevance of the identified SNP associations, a number of bioinformatics tools were used. These included the RegulomeDB (http://regulome.stanford.edu/), 22 which was used to investigate possible regulatory effects of the identified alleles or of other alleles in the surrounding region, and HaploReg v4.1 23 which facilitated the identification of other SNPs in high LD with the variants in our study. We also used GTEX 24 to identify eQTLs.
Results
Data filtering and quality control
Quality control results for the genotyping of the first study phase have been reported elsewhere. 17 Three SNPs were selected for genotyping in phase II, because of the association found with risk of BCIS (p < 0.001). None of these SNPs were out of HWE in the controls. The quality control analysis showed a concordance rate of 100% between duplicate samples for each of the SNP tested. The mean SNP call rate 
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was 99.36%, with the lowest (98.55%) observed for rs10500204 and the highest (99.88%) for rs238112. The variants in these analyses were already investigated in relation to invasive BC, but no significant associations were detected. 17 However, any association with BCIS specific risk remains unclear for these SNPs. 17 
SNPs main results
The adjusted threshold for statistical significance was set to p 5 0.05/1,065 5 4.6 3 10
25
, since the M eff was found to be 1,065.
In the first phase of our study, we identified three SNPs (ACVR2A-rs2382112, INSR-rs10500204 and MAST2-rs12124649) that were associated with increased risk of developing BCIS (p < 0.001). All three associations were found when comparing homozygotes for the minor allele with those who were homozygous for the common allele in the codominant model. The lowest p value was observed for the carriers of the major allele (A) of INSR-rs10500204 with an OR hom 5 2.08, 95% CI 5 1.39-3.10, P hom 5 3.52 3 10
24
). The other two signals were ACVR2A-rs2382112 with an OR hom 5 3.48, 95% CI 5 1.69-7.18, P hom 5 7.22 3 10
; and MAST2-rs12124649 with an OR hom 5 2.23, 95% CI 5 1.40-3.57, P hom 5 7.92 3 10
. The results for all the 1,414 polymorphic variants of phase I are reported in Supporting Information Table S1 and the results of the three SNPs with p < 0.001 are reported in Table 2 . In phase II, these three variants were genotyped in an additional set of cases and controls from the BPC3 cohort. When considering only this second set of individuals, the associations with BCIS risk were nominally significant for INSR-rs10500204 with an OR hom 5 1.68, 95% CI 5 1.03-2.74, P hom 5 0.037. When analyzing all the individuals together strong associations between all three SNPs and increased risk of developing BCIS were observed. In particular, for INSR-rs10500204 the association was significant after correcting for multiple testing (OR hom 5 1.96, 95% CI 5 1.44-2.67, P hom 5 1.68 3 10
25
), whereas for the other two SNPs the associations were consistent with the results in phase I but did not reach statistical significance after Bonferroni's correction. The results of all stages of the analysis are shown in Table 2 .
Case-only analyses
In the case-only analyses (BCIS vs. invasive BC) none of the associations were significant accounting for multiple testing. The result with the lowest p value was observed for INSRrs10500204 (OR hom 5 1.78, 95% CI 5 1.30-2.44, P hom 5 3.23 3 10
24
) indicating a stronger association with BCIS (Table 3) .
Ductal carcinoma in situ
Finally, the risk association with DCIS was investigated for all three SNPs showing a significant association with risk of DCIS in phase I, but none of the associations reached nominal statistical significance (Table 4) .
In silico analyses
The INSR-rs10500204 SNP, which showed a significant association with BCIS risk, was investigated further in terms of possible functional relevance. According to information derived from the RegulomeDB (http://regulome.stanford.edu/ ), 22 rs10500204 is likely to affect binding (RegulomeDB score 5 2b) of the following proteins: promyelocytic leukemia (PML), DNA-binding protein Ikaros (IKZF1), Nuclear factor of activated T-cells, cytoplasmic 1 (NFATC1) and Max-interacting protein 1 (MXI1). The binding was predicted by the software in lymphoblastic cell lines. Additionally, using HaploReg v4.1, 23 35 SNPs in moderate to high LD (R 2 > 0.6) with rs10500204 were identified. Out of these 35
SNPs, HaploReg provided information on functionality for only four (rs3815902, rs2059806, rs3786681, rs6510956), and none of them appeared to be functionally related to BCIS. In addition, for all of these 35 SNPs, the RegulomeDB indicated either that they were less likely to affect binding or that 24 we did not observe any significant eQTL results that were relevant for our analyses.
Discussion
The aim of our study was to identify novel BCIS risk variants. This was carried out, analyzing 1,414 common SNPs in 1,062 BCIS cases and 10,126 controls, as well as 6,113 invasive BC cases from the BPC3.
The most interesting results of our study was the significant association between INSR-rs10500204 and risk of BCIS, where two copies of the common (A)-allele were associated with an almost twofold increased risk, compared to two copies of the rare C-allele (P hom 5 1.68 3 10
25
). The insulin receptor (INSR) gene codes for the insulin receptor which binds insulin and IGFs. Mutations in this gene have been involved in insulin resistance as well as in several types of obesity related invasive cancers, such as colorectal, pancreatic, liver and BC. 25, 26 In addition, plasma levels of IGF-1 and IGFBP3 have been suggested to increase the risk of premenopausal DCIS. 27 It is, therefore, reasonable to hypothesise that SNPs located in regions related to these growth factors could influence BCIS risk.
The SNP rs10500204 is located in an intron of the INSR gene and according to information found in the RegulomeDB, it likely affects binding of the PML protein. Mutations in the PML gene have been related to various insulin resistance syndromes 28, 29 and the PML protein has been associated with tumor suppression in patients of acute PML 30 and is also known to be a tumor suppressor and growth regulator in cancer. 31 Loss of PML gene expression has been associated with progression of primary breast tumors to lymph node metastases 32 and PML expression in BC has also been associated with reduced time until recurrence. 31 Taken together, this information suggests a protective effect of the PML gene on tumorigenesis, and one might hypothesize that the Aallele of rs10500204 could decrease the effect of the PML gene while the minor allele (C) enhances the binding of PML to the INSR gene. However, further investigation is needed to confirm this and to identify the exact biological mechanism through which the alleles operate.
Our study focuses on selected SNPs in genes related to steroid hormone metabolism and IGF-1-pathways that are known to be involved in breast carcinogenesis. Thus, our findings should be interpreted against the background of a greater than average prior probability of finding associations with disease risk, compared to random SNP variants in the overall genome. The two stage design with the subsequent genotyping allowed a cost-effective increase in statistical power for the potentially interesting associations discovered in the first stage, through extension of the phase I study. Overall, our study is one of the larger efforts made to investigate BCIS specific associations of SNPs in regions related to metabolism of steroid hormones and IGF-1.
While there are genetic risk factors which are specific for either lobular or ductal BC, 14, 16 a limitation of our study was that the information on histological subtype of the tumors was relatively sparse and so the power to detect DCIS specific associations was limited. Taken together, our study provides a first indication of a possible association between the A-allele of INSR-rs10500204 and BCIS risk. While this finding could be plausible, further epidemiologic studies are needed to confirm this finding, and functional studies are required to verify the hypothesized biological mechanism.
